A Study of LY3305677 in Participants With Type 2 Diabetes

NCT03928379 · Completed

Last updated 2026-05-28

This study tests the safety of the experimental drug LY3305677 in adults with type 2 diabetes by monitoring for any serious side effects that may be linked to the medication.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 24 people

Who can join Ages 20–69 · all sexes

Timeline Started 2019-10 · est. completion 2021-07

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT03928379 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes. The study will last about 20 weeks for each participant, not including screening.

Treatments tested

LY3305677 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03928379 ↗